Reaction
Tumour Marker Abnormal reporting signals
As of the last recalculation, Tumour Marker Abnormal appears in 331 FAERS reports alongside 15 co-occurring drug terms. The strongest observed disproportionality signal is RIBOCICLIB (PRR 137.0).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Ribociclib | 57 | 137.0 | 137.2 |
| Fulvestrant | 53 | 119.9 | 120.1 |
| Exemestane | 27 | 86.2 | 86.3 |
| Ado-Trastuzumab Emtansine | 11 | 84.8 | 84.9 |
| Alpelisib | 11 | 82.0 | 82.1 |
| Letrozole | 57 | 70.1 | 70.2 |
| Letrozole Tablets | 45 | 67.9 | 68.0 |
| Anastrozole Tablets | 20 | 62.3 | 62.4 |
| Niraparib | 20 | 60.2 | 60.3 |
| Olaparib | 17 | 53.8 | 53.9 |
| Palbociclib | 62 | 50.1 | 50.1 |
| Abemaciclib | 13 | 42.5 | 42.6 |
| Fam-Trastuzumab Deruxtecan-Nxki | 4 | 25.2 | 25.3 |
| Gemcitabine | 15 | 25.0 | 25.0 |
| Rucaparib | 3 | 21.5 | 21.6 |